Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone in adolescents with schizophrenia
2013-001695-38Phase 3Completed
- Sponsor
- Sunovion
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lurasidone in schizophrenia (3 arms), sponsored by Sunovion. Primary endpoint: Change from baseline to Week 6 in Positive and Negative Syndrome Scale total score. Started Nov 2013; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2013-001695-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001695-38.